Loading patent…
AssigneesThe United States of America, as represented by the Secretary, Department of Health and Human Services, Universitatsklinikum Freiburg
InventorsWilliam D. Figg, Klaus Mross, Dirk Behringer, Alex Sparreboom, Tristan Sissung, Stephan Mielke
Estimating the term…
The present disclosure provides methods of identifying subjects having an increased likelihood of developing one or more adverse side effects resulting from administration of a microtubule-stabilizing agent. In particular examples, the method includes determining whether the subject has an ABCB1 predictive polymorphism for microtubule-stabilizing agent-induced toxicity, wherein the presence of such a polymorphism indicates that the subject has an increased risk of developing microtubule-stabilizing agent induced adverse effects. Examples of ABCB1 predictive polymorphisms include 2677G>T/A and 3435C>T. Also provided are methods of modifying microtubule-stabilizing agent therapy in a subject identified as having one or more ABCB1 predictive polymorphisms. Kits and isolated nucleic acid molecules that can be used in the disclosed methods are also provided.
A method for identifying a subject at increased risk for developing microtubule-stabilizing-agent-induced adverse effects, comprising determining whether the subject has at least one predictive polymorphism in an ABCB1 gene, wherein the predictive polymorphism comprises one or more of:
(canceled)
(canceled)
A method for decreasing occurrence of microtubule-stabilizing-agent-induced adverse effects in a subject having a disorder which can be treated with a therapeutically effective amount of a microtubule-stabilizing agent, comprising determining whether the subject has at least one predictive polymorphism in an ABCB1 gene, wherein the predictive polymorphism comprises one or more of:
(canceled)
An isolated nucleic acid consisting of any of the nucleotide sequences shown in SEQ ID NOs:
(canceled)
(canceled)
A kit for identifying a subject at increased risk for microtubule-stabilizing-agent-induced adverse effects, comprising one or more reagents for detecting at least one predictive polymorphism in an ABCB1 gene, wherein the predictive polymorphism comprises:
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.